XW0V0P7
Introduction Bones to New Technology Group 7 with Antibiotic-eluting Bone Void Filler, Open Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | X New Technology |
| Body System | W Anatomical Regions |
| Operation | 0 Introduction |
| Body Part | V Bones |
| Approach | 0 Open |
| Device | P Antibiotic-eluting Bone Void Filler |
| Qualifier | 7 New Technology Group 7 |
Operation Definition
Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
Procedure Overview
This family covers putting a therapeutic, diagnostic, nutritional, or preventive substance into or onto a body region, using a product recently approved under the New Technology pathway rather than an established drug or agent. It is not tied to one organ system but to broader anatomical regions, which is used when the substance is delivered in a way that does not target a single specific body part.
Clinically, this might apply to a patient receiving a newly approved anti-infective, an engineered biologic, or another agent whose novelty is what earns it separate tracking, often because it addresses a resistant infection or a condition that standard substances do not adequately treat.
Anatomy & Axis Detail
Bones
Bones as the target of a New Technology introduction procedure typically involves placing a novel osteobiologic, antimicrobial, or regenerative substance directly into osseous tissue, for example to combat resistant osteomyelitis or promote healing in a nonunion fracture. Bone's dense, mineralized structure limits diffusion of systemically administered drugs, which is precisely why local introduction into the bone itself is chosen when a targeted concentration at the site of disease is needed. Because this code applies to bones as a general category rather than one named bone, the operative documentation should make clear that the substance was delivered into osseous tissue broadly, and identify the specific New Technology agent used. Accurate coding here helps distinguish investigational bone-directed therapies from established graft or antibiotic bead procedures already captured elsewhere in ICD-10-PCS.
Approach: Open
Open approach in New Technology denotes access to the target site through a surgical incision that exposes the body part directly to view and instrumentation. It stands apart from percutaneous and endoscopic approaches, which achieve access through small punctures or existing openings rather than a deliberate surgical opening of tissue.
Device / Substance / Technology: Antibiotic-eluting Bone Void Filler
Antibiotic-eluting Bone Void Filler denotes use of a bone graft substitute impregnated with antibiotic that releases the drug locally over time to reduce infection risk while filling a skeletal defect, often after debridement of infected bone. It differs from the peptide-enhanced and AGN1 fillers, which prioritize bone regeneration and mineral scaffolding rather than sustained local antibiotic delivery.
Qualifier: New Technology Group 7
As a qualifier value, Group 7 marks a code as belonging to the set of new technologies approved for use in the 2020-2021 fiscal year, a period that included a notable expansion of infectious-disease-related add-on codes. The label does not describe what the technology does; that detail sits in the table and other axis values. It is distinguished from adjoining groups solely by its approval-year cohort.
Coding & Documentation
Coders need the medication administration record or physician note to name the specific substance given and confirm it is one recognized under the current New Technology list, since this family exists specifically to track these products separately from routine drug administration. The route and anatomical region also need to be clearly stated.
A common error is coding a routine medication administration under this family simply because it sounds unfamiliar, when in fact only substances formally approved under the New Technology pathway qualify. Another is missing the code entirely when a newly approved agent is documented only by a shorthand or trade name the coder does not recognize.
Commonly Confused With
This is frequently confused with standard Administration section codes used for everyday medications and fluids. The distinguishing factor is strictly whether the substance itself has New Technology approval, since the delivery method and clinical intent can look identical to a routine medication given for the same reason.